Pregabalin Capsule
Product Images NDC 55700-964

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 55700-964). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (1)

This is a warning label for Pregabalin capsules manufactured by ScieGen Pharmaceuticals. The label provides information on dosage, ingredients, and potential side effects. It also warns that the medication may be habit-forming and should be kept out of the reach of children. The manufacturing company's address is also provided.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

The text seems to be a chart displaying the percentage of patients who have improved, with some numbers slightly shifted and the addition of a line that says "Percent Improvement in Pain from Baseline". Without additional context, it is difficult to provide a more specific description.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

The text suggests that there is a table or graph showing percent improvement in pain from baseline for patients who took Pregabalin 160 mg for three days. The data includes percentages of improvement ranging from 2 to 100 percent. However, there are some random numbers and symbols that do not seem to fit in, and the text does not provide a clear description of the entire chart or table. Therefore, the information provided is not helpful.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

This text appears to be a chart displaying the percentage of patients improved and the percentage improvement in pain from baseline for different medications, including Pregatalin and Pregabalin. The chart also includes some numerical values that are difficult to interpret, as they are not arranged in a clear format.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

Not available.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

This looks like a table showing the dosage of two medications (Fregabalin and Pregataiin) as well as a placebo, and the percentage of patients who experienced improvement in pain after taking them. There is also a chart showing the percentage of improvement in pain from baseline for each treatment. It appears that Fregabalin was given at a higher dose than Pregataiin, but it is not clear what condition the patients were being treated for.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

The text appears to be a table representing a study with different dosages of a medication (Placebo, 50mg/day, 150mg/day, 300mg/day, 600mg/day) and its effects. The text mentions that the study was statistically significant compared to the placebo group.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

This is a graph depicting the percent of patients who showed improvement in pain based on different doses of Pregabalin (300mg and 450mg) as well as placebo. The x-axis shows the percent improvement in pain from baseline while the y-axis shows the percentage of patients who experienced a specific level of pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a chart displaying the estimated percentage of subjects without LTR (likely a medical term) over a period of 120 days. There are two sections labeled "Progabain" and "Placebo." The percentages range from 100% down to 0%, and there are various markers for each 10-day interval. It is not clear what LTR refers to or what study this chart is from.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text seems to show a chart or table that displays the percentage of subjects who have improved. There are two groups, one that received pregabalin and one that received a placebo. The percentage of improvement is shown from baseline up to week 16. However, as the text is not clear, there may be some discrepancies or errors in the interpretation of the data.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This appears to be a formula used to calculate the creatinine clearance (CLCT) of a patient based on their age, weight, and serum creatinine level. The formula involves subtracting the patient's age in years from 140 and multiplying the result by their weight in kilograms. For female patients, the result is then multiplied by 0.85. The final step involves multiplying the result by the patient's serum creatinine level measured in milligrams per deciliter (mg/dL), and dividing by 72. This formula is often used to estimate kidney function in patients with renal impairment.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.